Bio-Gene Technology (ASX:BGT) Net Issuance of Preferred Stock : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Bio-Gene Technology Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Bio-Gene Technology's net issuance of preferred for the six months ended in Dec. 2023 was A$0.00 Mil. The number is 0, which means that Bio-Gene Technology has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Bio-Gene Technology's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Bio-Gene Technology Net Issuance of Preferred Stock Historical Data

The historical data trend for Bio-Gene Technology's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Gene Technology Net Issuance of Preferred Stock Chart

Bio-Gene Technology Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Bio-Gene Technology Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial								-	-	-	-	-

Bio-Gene Technology Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Bio-Gene Technology Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Bio-Gene Technology's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Gene Technology (ASX:BGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Gene Technology Ltd (ASX:BGT) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000

Website

https://www.bio-gene.com.au

Bio-Gene Technology Ltd is an Australian biotechnology company engaged in the development and commercialization of insecticide products. It develops a patent-protected product platform based on a naturally occurring class of chemicals known as beta-triketones. Its product includes Qcide and Flavocid. Its target applications include agriculture, public health, and consumer and animal health. The firm operates in one business segment namely the conduct of research and development activities in the discovery of novel insecticides.

Bio-Gene Technology (ASX:BGT) Headlines

From GuruFocus

Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

By Business Wire Business Wire • 12-20-2021